Current Report Filing (8-k)
February 27 2017 - 4:09PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
____________
FORM 8-K
____________
Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
Reported): February 27, 2017
____________
THERAVANCE BIOPHARMA, INC.
(Exact Name of Registrant as Specified in
its Charter)
____________
Cayman Islands
(State or Other Jurisdiction of Incorporation)
|
001-36033
(Commission File Number)
|
98-1226628
(I.R.S. Employer Identification Number)
|
PO Box
309
Ugland
House, South Church Street
George
Town, Grand Cayman, Cayman Islands KY1-1104
(650)
808-6000
(Addresses, including zip code, and telephone
number, including area code, of principal executive offices)
____________
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02. Results of Operations and Financial Condition.
On February 27, 2017, Theravance Biopharma, Inc. issued
a press release and is holding a conference call regarding its financial results for the quarter and year ended December 31,
2016 and a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.
The information in Item 2.02 and in Item 9.01 of this Current
Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act of 1934"), or otherwise subject to
the liabilities of that Section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended,
or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press Release dated February 27, 2017
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
THERAVANCE BIOPHARMA, INC.
|
|
|
|
|
|
|
|
|
Date: February 27, 2017
|
|
By:
|
/s/ Renee D. Gala
|
|
|
|
Renee D. Gala
|
|
|
|
Senior Vice President and Chief Financial Officer
|
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
99.1
|
|
Press Release dated February 27, 2017
|
Theravance Biopharma (NASDAQ:TBPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Theravance Biopharma (NASDAQ:TBPH)
Historical Stock Chart
From Apr 2023 to Apr 2024